For how we live.
The agency is describing the trial design it is weighing for ibogaine, a psychedelic with serious cardiac risks, as HHS funds the first federal studies in opioid use disorder and PTSD. Comments close 20 November.
For a few seconds to a couple of minutes you are awake but frozen, sometimes with a sense of a presence in the room. It is REM sleep intruding into wakefulness — common, frightening and, on its own, harmless.
Nightmare disorder affects about 4% of adults. The treatment with the clearest backing is not a drug but a rehearsal technique that rewrites the dream while you are awake.
In a 304-veteran trial, prazosin matched placebo on trauma nightmares and sleep quality. Sleep medicine's one recommended treatment for nightmare disorder is a behavioural therapy, not a drug.
In the largest network meta-analysis, EMDR and trauma-focused CBT were the most effective treatments for adults with PTSD. The evidence is graded moderate-to-low, and the eye movements may not be why it works.
The federal program enrols nearly 140,000 responders and survivors, most certified for a 9/11-related illness. Cohort data show a heavy, still-growing burden — and hint the program itself lowers mortality.
Registry and responder cohorts document persistent PTSD and depression, a symptom peak more than a decade after the attacks, and a burden that compounds with chronic physical illness.
A five-year panel study found sales of mental-disorder medicines rose 144% in a cyclone's landfall year and 173% the next in coastal districts, with no measurable effect further inland.
Among 383 dialysis patients, 83.6% screened for moderate-to-extreme anxiety and 58% for PTSD; a separate study of 250 displaced adolescents found trauma exposure tracking closely with post-traumatic symptoms.
Dronabinol beat placebo on a nightmare-severity scale in 171 adults, but the effect was moderate and the only serious adverse events occurred in the drug group. Long-term safety is untested.
The INTERSECT study asked 11,302 women 6 to 12 weeks postpartum about birth trauma. The spread between countries is far wider than the average, and that is the finding.
The agency compressed review of three psychedelic therapies from a year to weeks. A first approval decision is plausible by early 2027.
A cross-sectional study of 96 war amputees, 53 caregivers and 95 community controls found sharply elevated disability and psychiatric symptoms, and argued for combined physical and mental-health rehabilitation.
A systematic review screened 3,857 records and found three eligible studies, every one produced by a US commercial provider and every one at critical risk of bias.
Anxiety, quality of life and PTSD symptoms all improved after a single dose in this 15-person trial. Once researchers accounted for depression improvement, those effects mostly disappeared.
TSND-201 improved PTSD severity, disability, and depression scores over placebo in 65 participants — delivered as an oral dose with monitoring but no formal psychotherapy alongside it.
A survey of 243 people reporting persistent difficulty after a psychedelic trip found that how they responded in the moment, avoiding versus accepting, predicted whether trauma symptoms followed.
In 99 men hospitalised for stress-related disorders, roughly four in five met probable criteria for trauma-associated sleep disorder — a condition that is not yet a recognised diagnosis.